Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Looking for a particular Vivet Therapeutics employee's phone or email?
The Vivet Therapeutics annual revenue was $1 million in 2026.
Jean-Philippe Combal is the Co-Founder and Chief Executive Officer of Vivet Therapeutics.
18 people are employed at Vivet Therapeutics.
Vivet Therapeutics is based in Paris, Île-de-France.
The NAICS codes for Vivet Therapeutics are [54, 541, 54171, 541714, 5417].
The SIC codes for Vivet Therapeutics are [873, 87].